Shares of CSTONE PHARMA-B (ASX: 02616) rose nearly 5% during the late trading session. As of the latest update, the stock was up 4.26% to HK$4.65, with a turnover of HK$36.4976 million.

Clinical Development Milestone

The company announced that its Pipeline 2.0 core candidate drug, CS5007, has received approval from the Australian Human Research Ethics Committee (HREC) to commence a global multi-center Phase I clinical trial. CS5007 is an EGFR/HER3 bispecific antibody-drug conjugate (ADC). This approval signifies the full launch of the drug's global clinical development and indicates that the company's Pipeline 2.0 strategy is accelerating, with subsequent major assets entering the clinical fast track. This progress is expected to bolster confidence in the company's medium to long-term growth prospects.

Insider Confidence and Analyst View

It is noteworthy that the company has recently seen share purchases by several directors. Analysts from Jefferies noted that the planned share purchases by the management and board fully demonstrate their high confidence in the progress of the company's pipeline business development. Management has indicated that the current stock price is significantly undervalued, reflecting optimism regarding the ongoing licensing negotiations for CS2009.

Pipeline Asset Potential

Data presented by the company at the 2026 ASCO meeting showed that CS2009 delivered solid efficacy and a favorable safety profile in non-small cell lung cancer and various cold tumors. This positions it as a potential next-generation foundational immuno-oncology therapy with best-in-class potential.